To ask the Secretary of State for Health and Social Care, whether specialist multidisciplinary teams and designated centres of excellence will be given clear guidance and authority to prescribe off-label treatments supported by genomic evidence and aligned with patient preference for patients with rare cancers.
The Medicines and Healthcare products Regulatory Agency (MHRA) and the National Institute for Health and Care Excellence (NICE) are working to deliver the Government’s ambitions, as set out in the 10-Year Health Plan for England and the Life Sciences Sect...
Rare Cancers: Medical Treatments